Lakefront Biotherapeutics (LKFT)
Develops and acquires autoimmune T-cell engager medicines with Gilead.
$28.99
Pre-market+0.17 (+0.61%)
At close$28.82(+0.93%)
Something off on this page? Send us feedback.
Next report
Nov 12, 2026
in 70 days
EPS estimate
−$0.82
Revenue estimate
$9.0M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25Apr '25Jul '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$0.30−$2.67−$1.85−$3.54$13.90$0.25$0.03Pending
Estimate−$0.55−$0.14−$0.23−$0.48−$0.13−$0.94−$0.15−$0.82
Surprise+155.1%−1,783.0%−711.8%−641.4%+11,077.7%+126.2%+123.1%—
RevenueReportedEstimate
Feb '25Apr '25Jul '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$79.3M$85.3M$76.8M$82.1M$1.05B$7.6M$14.0MPending
Estimate$77.0M$71.9M$80.1M$76.1M$82.9M$9.6M$14.0M$9.0M
Surprise+3.0%+18.6%−4.1%+7.9%+1,166.2%−20.4%+0.3%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.82 | — | — |
| Aug 2026 | −$0.15 | $0.03 | +123.1% |
| May 2026 | −$0.94 | $0.25 | +126.2% |
| Feb 2026 | −$0.13 | $13.90 | +11,077.7% |
| Nov 2025 | −$0.48 | −$3.54 | −641.4% |
The latest year is open to everyone — the 5 quarters behind it read with an account. Sign in | |||
| Jul 2025 | |||
| Apr 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | −$0.82 | — | — | $9.0M | — | — | — |
| Aug 10, 2026 | −$0.15 | $0.03 | +123.1% | $14.0M | $14.0M | +0.3% | +6.8% |
| May 6, 2026 | −$0.94 | $0.25 | +126.2% | $9.6M | $7.6M | −20.4% | −3.8% |
| Feb 23, 2026 | −$0.13 | $13.90 | +11,077.7% | $82.9M | $1.05B | +1,166.2% | +1.5% |
| Nov 5, 2025 | −$0.48 | −$3.54 | −641.4% | $76.1M | $82.1M | +7.9% | +4.4% |
The latest year is open to everyone — the 5 quarters behind it read with an account. Sign in | |||||||
| Jul 23, 2025 | |||||||
| Apr 23, 2025 | |||||||
| Feb 12, 2025 | |||||||
| Oct 30, 2024 | |||||||
| Aug 1, 2024 | |||||||